Ginsenoside Rg1 inhibits inflammatory responses via modulation of the nuclear factor‑κB pathway and inhibition of inflammasome activation in alcoholic hepatitis Corrigendum in /10.3892/ijmm.2024.5407

Li,Jiajun; Yang,Cheng; Zhang,Shu; Liu,Shu; Zhao,Luole; Luo,Huan; Chen,Yatang; Huang,Wenxiang

doi:10.3892/ijmm.2017.3297

Ginsenoside Rg1 inhibits inflammatory responses via modulation of the nuclear factor‑κB pathway and inhibition of inflammasome activation in alcoholic hepatitis

Corrigendum in 10.3892/ijmm.2024.5407

Authors:
- Jiajun Li
- Cheng Yang
- Shu Zhang
- Shu Liu
- Luole Zhao
- Huan Luo
- Yatang Chen
- Wenxiang Huang
View Affiliations

Affiliations: Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: November 29, 2017 https://doi.org/10.3892/ijmm.2017.3297
Pages: 899-907
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ginsenoside Rg1 (G‑Rg1) is an active ingredient of Panax ginseng, which has previously been reported to attenuate alcohol‑induced hepatic damage; however, the underlying mechanisms remain largely unknown. The present study aimed to investigate the protective effects of G‑Rg1 on alcohol‑induced cell injury in vitro and on a rat model of alcoholic hepatitis in vivo. For the in vitro model, L‑O2 cells were incubated with ethanol in the presence or absence of G‑Rg1. For the in vivo model, rats were administered ethanol by intragastric injection and were treated with G‑Rg1, or dexamethasone as a control. The results indicated that serum biochemical parameters, including alanine aminotransferase, aspartate aminotransferase and total bilirubin, as well as the expression of nuclear factor (NF)‑κB pathway‑associated inflammatory cytokines, including interleukin (IL)‑6, tumor necrosis factor‑α and IL‑1β, were elevated in response to alcohol; however, they were significantly decreased by G‑Rg1 treatment. Furthermore, NF‑κB pathway activation was reduced by treatment with G‑Rg1. G‑Rg1 also decreased oxidative stress by inhibiting cytochrome P450 2E1 expression and reactive oxygen species production, and promoting glutathione peroxidase expression. Furthermore, G‑Rg1 inhibited the expression levels of caspase‑3 and ‑8, which may be associated with decreased hepatocyte apoptosis. These data suggested that G‑Rg1 may protect hepatocytes against alcohol‑induced injury, through preventing excessive inflammation and hepatocellular apoptosis.

View Figures

View References

1	Chang B, Li B, Huang A, Sun Y, Teng G, Wang X, Liangpunsakul S, Li J and Zou Z: Changes of four common non-infectious liver diseases for the hospitalized patients in Beijing 302 hospital from 2002 to 2013. Alcohol. 54:61–65. 2016. View Article : Google Scholar : PubMed/NCBI
2	Wang H, Ma L, Yin Q, Zhang X and Zhang C: Prevalence of alcoholic liver disease and its association with socioeconomic status in north-eastern China. Alcohol Clin Exp Res. 38:1035–1041. 2014. View Article : Google Scholar : PubMed/NCBI
3	Iwaisako K, Brenner DA and Kisseleva T: What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol. 27(Suppl 2): 65–68. 2012. View Article : Google Scholar : PubMed/NCBI
4	Schattenberg JM, Galle PR and Schuchmann M: Apoptosis in liver disease. Liver Int. 26:904–911. 2006. View Article : Google Scholar : PubMed/NCBI
5	Zakhari S and Li TK: Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. Hepatology. 46:2032–2039. 2007. View Article : Google Scholar : PubMed/NCBI
6	You M and Crabb DW: Recent advances in alcoholic liver disease II. Minireview: Molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol. 287:G1–G6. 2004. View Article : Google Scholar : PubMed/NCBI
7	Nagata K, Suzuki H and Sakaguchi S: Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci. 32:453–468. 2007. View Article : Google Scholar
8	Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M, Yamashina S, Schemmer P, Kitamura T, Oide H, et al: Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. J Gastroenterol Hepatol. 15(Suppl): D20–D25. 2000. View Article : Google Scholar : PubMed/NCBI
9	Gao B: Cytokines, STATs and liver disease. Cell Mol Immunol. 2:92–100. 2005.PubMed/NCBI
10	Friedman SL: Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 88:125–172. 2008. View Article : Google Scholar : PubMed/NCBI
11	Xie XS, Liu HC, Wang FP, Zhang CL, Zuo C, Deng Y and Fan JM: Ginsenoside Rg1 modulation on thrombospondin-1 and vascular endothelial growth factor expression in early renal fibro-genesis in unilateral obstruction. Phytother Res. 24:1581–1587. 2010. View Article : Google Scholar : PubMed/NCBI
12	Xu L, Chen WF and Wong MS: Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway. Br J Pharmacol. 158:738–748. 2009. View Article : Google Scholar : PubMed/NCBI
13	Shen LH and Zhang JT: Ginsenoside Rg1 promotes proliferation of hippocampal progenitor cells. Neurol Res. 26:422–428. 2004. View Article : Google Scholar : PubMed/NCBI
14	Shi AW, Wang XB, Lu FX, Zhu MM, Kong XQ and Cao KJ: Ginsenoside Rg1 promotes endothelial progenitor cell migration and proliferation. Acta Pharmacol Sin. 30:299–306. 2009. View Article : Google Scholar : PubMed/NCBI
15	Wu CF, Bi XL, Yang JY, Zhan JY, Dong YX, Wang JH, Wang JM, Zhang R and Li X: Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia. Int Immunopharmacol. 7:313–320. 2007. View Article : Google Scholar : PubMed/NCBI
16	Wu F, Zhang SS and Kang GF: Effects of panax notoginseng saponins on the expression of tumor necrosis factor alpha and secretion phospholipase A2 in rats with liver fibrosis. Zhonghua Gan Zang Bing Za Zhi. 11:51–52. 2003.In Chinese. PubMed/NCBI
17	Gao Y, Chu S, Li J, Li J, Zhang Z, Xia C, Heng Y, Zhang M, Hu J, Wei G, et al: Anti-inflammatory function of ginsenoside Rg1 on alcoholic hepatitis through glucocorticoid receptor related nuclear factor-kappa B pathway. J Ethnopharmacol. 173:231–240. 2015. View Article : Google Scholar : PubMed/NCBI
18	Tao T, Chen F, Bo L, Xie Q, Yi W, Zou Y, Hu B, Li J and Deng X: Ginsenoside Rg1 protects mouse liver against ischemia-reper-fusion injury through anti-inflammatory and anti-apoptosis properties. J Surg Res. 191:231–238. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhang XJ, He C, Li P, Su H and Wan JB: Ginsenoside Rg1, a potential JNK inhibitor, protects against ischemia/reperfusion-induced liver damage. J Funct Foods. 15:580–592. 2015. View Article : Google Scholar
20	Xin Y, Wei J, Chunhua M, Danhong Y, Jianguo Z, Zongqi C and Jian-An B: Protective effects of Ginsenoside Rg1 against carbon tetrachloride-induced liver injury in mice through suppression of inflammation. Phytomedicine. 23:583–588. 2016. View Article : Google Scholar : PubMed/NCBI
21	Geng J, Peng W, Huang Y, Fan H and Li S: Ginsenoside-Rg1 from Panax notoginseng prevents hepatic fibrosis induced by thioacetamide in rats. Eur J Pharmacol. 634:162–169. 2010. View Article : Google Scholar : PubMed/NCBI
22	Li JP, Gao Y, Chu SF, Zhang Z, Xia CY, Mou Z, Song XY, He WB, Guo XF and Chen NH: Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol- and CCl₄ -induced hepatic fibrosis. Acta Pharmacol Sin. 35:1031–1044. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zhao J, Shi Z, Liu S, Li J and Huang W: Ginsenosides Rg1 from Panax ginseng: A potential therapy for acute liver failure patients. Evid Based Complement Alternat Med. 538059:2014. View Article : Google Scholar
24	Bieghs V and Trautwein C: The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 34:446–452. 2013. View Article : Google Scholar : PubMed/NCBI
25	Tsukamoto H, Reidelberger RD, French SW and Largman C: Long-term cannulation model for blood sampling and intragastric infusion in the rat. Am J Physiol. 247:R595–R599. 1984.PubMed/NCBI
26	Tsukamoto H, Horne W, Kamimura S, Niemelä O, Parkkila S, Ylä-Herttuala S and Brittenham GM: Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 96:620–630. 1995. View Article : Google Scholar : PubMed/NCBI
27	Sedlak J and Lindsay RH: Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 25:192–205. 1968. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
29	Santos Rocha SW, Silva BS, Gomes FO, Soares e Silva AK, Raposo C, Barbosa KP, Torres DO, dos Santos AC and Peixoto CA: Effect of diethylcarbamazine on chronic hepatic inflammation induced by alcohol in C57BL/6 mice. Eur J Pharmacol. 689:194–203. 2012. View Article : Google Scholar : PubMed/NCBI
30	Singal AK, Kodali S, Vucovich LA, Darley-Usmar V and Schiano TD: Diagnosis and treatment of alcoholic hepatitis: A systematic review. Alcohol Clin Exp Res. 40:1390–1402. 2016. View Article : Google Scholar : PubMed/NCBI
31	Szabo G and Csak T: Inflammasomes in liver diseases. J Hepatol. 57:642–654. 2012. View Article : Google Scholar : PubMed/NCBI
32	Walker RK, Cousins VM, Umoh NA, Jeffress MA, Taghipour D, Al-Rubaiee M and Haddad GE: The good, the bad, and the ugly with alcohol use and abuse on the heart. Alcohol Clin Exp Res. 37:1253–1260. 2013. View Article : Google Scholar : PubMed/NCBI
33	Rehm J, Samokhvalov AV and Shield KD: Global burden of alcoholic liver diseases. J Hepatol. 59:160–168. 2013. View Article : Google Scholar : PubMed/NCBI
34	Liu J, Wang X, Liu R, Liu Y, Zhang T, Fu H and Hai C: Oleanolic acid co-administration alleviates ethanol-induced hepatic injury via Nrf-2 and ethanol-metabolizing modulating in rats. Chem Biol Interact. 221:88–98. 2014. View Article : Google Scholar : PubMed/NCBI
35	Zou Y, Tao T, Tian Y, Zhu J, Cao L, Deng X and Li J: Ginsenoside Rg1 improves survival in a murine model of polymicrobial sepsis by suppressing the inflammatory response and apoptosis of lymphocytes. J Surg Res. 183:760–766. 2013. View Article : Google Scholar : PubMed/NCBI
36	Shen L and Zhang J: Ginsenoside Rg1 increases ischemia-induced cell proliferation and survival in the dentate gyrus of adult gerbils. Neurosci Lett. 344:1–4. 2003. View Article : Google Scholar : PubMed/NCBI
37	Karikura M, Tanizawa H, Hirata T, Miyase T and Takino Y: Studies on absorption, distribution, excretion and metabolism of ginseng saponins. VIII. Isotope labeling of ginsenoside Rb2. Chem Pharm Bull (Tokyo). 40:2458–2460. 1992. View Article : Google Scholar
38	Kubes P and Mehal WZ: Sterile inflammation in the liver. Gastroenterology. 143:1158–1172. 2012. View Article : Google Scholar : PubMed/NCBI
39	Cao YW, Jiang Y, Zhang DY, Wang M, Chen WS, Su H, Wang YT and Wan JB: Protective effects of Penthorum chinense Pursh against chronic ethanol-induced liver injury in mice. J Ethnopharmacol. 161:92–98. 2015. View Article : Google Scholar
40	Ding RB, Tian K, Huang LL, He CW, Jiang Y, Wang YT and Wan JB: Herbal medicines for the prevention of alcoholic liver disease: A review. J Ethnopharmacol. 144:457–465. 2012. View Article : Google Scholar : PubMed/NCBI
41	Brenner C, Galluzzi L, Kepp O and Kroemer G: Decoding cell death signals in liver inflammation. J Hepatol. 59:583–594. 2013. View Article : Google Scholar : PubMed/NCBI